Patents by Inventor Béranger Duthion
Béranger Duthion has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12065443Abstract: The present invention discloses compounds according to Formula I: wherein R1, R2, R3a, R3b, X, Y1, Y2, Y3, and Z are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of TNF?, interferons, IL-6, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.Type: GrantFiled: April 13, 2022Date of Patent: August 20, 2024Assignee: GALAPAGOS NVInventors: Luke Jonathan Alvey, Denis Maurice Annoot, Florence Marie-Emilie Bonnaterre, Denis Bucher, Béranger Duthion, Hélène Marie Jary, Christophe Peixoto, Taoues Temal-Laib, Amynata Tirera, Nicolas Desroy
-
Publication number: 20220340548Abstract: The present invention discloses compounds according to Formula I: wherein R1a, R1b, R1c, R2a, W1, W2, X1, X2, X3, Y, and Z are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of IL-6, diseases associated with hypersecretion of TNF?, interferons, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.Type: ApplicationFiled: May 25, 2020Publication date: October 27, 2022Inventors: Luke Jonathan ALVEY, Denis BUCHER, Nicolas DESROY, Hélène Marie JARY, Christophe PEIXOTO, Taoues TEMAL-LAÏB, Amynata TIRERA, Florence Marie-Emilie BONNATERRE, Béranger DUTHION
-
Publication number: 20220340581Abstract: The present invention discloses compounds according to Formula I: wherein R1, R2, R3a, R3b, X, Y1, Y2, Y3, and Z are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of TNF?, interferons, IL-6, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.Type: ApplicationFiled: April 13, 2022Publication date: October 27, 2022Inventors: Luke Jonathan ALVEY, Denis Maurice ANNOOT, Florence Marie-Emilie BONNATERRE, Denis BUCHER, Béranger DUTHION, Hélène Marie JARY, Christophe PEIXOTO, Taoues TEMAL-LAIB, Amynata TIRERA, Nicolas DESROY
-
Patent number: 11339166Abstract: The present invention discloses compounds according to Formula I: wherein R1, R2, R3a, R3b, X, Y1, Y2, Y3, and Z are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of TNF?, interferons, IL-6, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.Type: GrantFiled: November 26, 2018Date of Patent: May 24, 2022Assignee: GALAPAGOS NVInventors: Luke Jonathan Alvey, Denis Maurice Annoot, Florence Marie-Emilie Bonnaterre, Denis Bucher, Béranger Duthion, Hélène Marie Jary, Christophe Peixoto, Taoues Temal-Laib, Amynata Tirera, Nicolas Desroy
-
Publication number: 20210315893Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, L, A1, A2, A3, Cy and the subscript n are as defined herein. The present invention relates to antagonists compounds of sphingosine 1-phosphate (S1P) receptor, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, inflammatory diseases, respiratory diseases, autoimmune diseases, metabolic diseases, cardiovascular diseases, and/or proliferative diseases by administering the compound of the invention.Type: ApplicationFiled: June 21, 2018Publication date: October 14, 2021Inventors: Oscar MAMMOLITI, Koen Karel JANSEN, Christel Jeanne Marie MENET, Adeline Marie Elise PALISSE, Giovanni Alessandro TRICARICO, Sandy EL BKASSINY, Alexis Patrick Claude JAUNET, Brigitte ALLART, Franck Laurent BREBION, Béranger DUTHION
-
Publication number: 20210101903Abstract: The present invention discloses compounds according to Formula I: wherein R1, R2, R3a, R3b, X, Y1, Y2, Y3, and Z are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of TNF?, interferons, IL-6, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.Type: ApplicationFiled: November 26, 2018Publication date: April 8, 2021Inventors: Luke Jonathan ALVEY, Denis Maurice ANNOOT, Florence Marie-Emilie BONNATERRE, Denis BUCHER, Béranger DUTHION, Hélène Marie JARY, Christophe PEIXOTO, Taoues TEMAL-LAIB, Amynata TIRERA, Nicolas DESROY
-
Patent number: 10647717Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).Type: GrantFiled: June 18, 2019Date of Patent: May 12, 2020Assignees: AbbVie S.á.r.l., Galapagos NVInventors: Rhalid Akkari, Luke Jonathan Alvey, Xavier Marie Bock, Brian S. Brown, Pieter Isabelle Roger Claes, Marlon D. Cowart, Elsa De Lemos, Nicolas Desroy, Béranger Duthion, Gregory A. Gfesser, Romain Luc Marie Gosmini, Christopher Gaëtan Housseman, Koen Karel Jansen, Jianguo Ji, Philip R. Kym, Jean-Michel Lefrancois, Oscar Mammoliti, Christel Jeanne Marie Menet, Nuria Merayo Merayo, Gregory John Robert Newsome, Adeline Marie Elise Palisse, Sachin V. Patel, Matthieu Rafaël Pizzonero, Anurupa Shrestha, Elizabeth C. Swift, Steven Emiel Van der Plas, Xueqing Wang, Ann de Blieck
-
Publication number: 20190330207Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).Type: ApplicationFiled: June 18, 2019Publication date: October 31, 2019Inventors: Rhalid Akkari, Luke Jonathan Alvey, Xavier Marie Bock, Brian S. Brown, Pieter Isabelle Roger Claes, Marlon D. Cowart, Elsa De Lemos, Nicolas Desroy, Béranger Duthion, Gregory A. Gfesser, Romain Luc Marie Gosmini, Christopher Gaëtan Housseman, Koen Karel Jansen, Jianguo Ji, Philip R. Kym, Jean-Michel Lefrancois, Oscar Mammoliti, Christel Jeanne Marie Menet, Nuria Merayo Merayo, Gregory John Robert Newsome, Adeline Marie Elise Palisse, Sachin V. Patel, Matthieu Rafaël Pizzonero, Anurupa Shrestha, Elizabeth C. Swift, Steven Emiel Van der Plas, Xueqing Wang, Ann de Blieck
-
Publication number: 20190202823Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).Type: ApplicationFiled: March 6, 2019Publication date: July 4, 2019Inventors: Rhalid Akkari, Luke Jonathan Alvey, Xavier Marie Bock, Brian S. Brown, Pieter Isabelle Roger Claes, Marlon D. Cowart, Elsa De Lemos, Nicolas Desroy, Béranger Duthion, Gregory A. Gfesser, Romain Luc Marie Gosmini, Christopher Gaëtan Housseman, Koen Karel Jansen, Jianguo Ji, Philip R. Kym, Jean-Michel Lefrancois, Oscar Mammoliti, Christel Jeanne Marie Menet, Nuria Merayo Merayo, Gregory John Robert Newsome, Adeline Marie Elise Palisse, Sachin V. Patel, Matthieu Rafaël Pizzonero, Anurupa Shrestha, Elizabeth C. Swift, Steven Emiel Van der Plas, Xueqing Wang, Ann de Blieck
-
Patent number: 10259810Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).Type: GrantFiled: December 15, 2017Date of Patent: April 16, 2019Assignees: AbbVie S.à.r.l., Galapagos NVInventors: Rhalid Akkari, Luke Jonathan Alvey, Xavier Marie Bock, Brian S. Brown, Pieter Isabelle Roger Claes, Marlon D. Cowart, Elsa De Lemos, Nicolas Desroy, Béranger Duthion, Gregory A. Gfesser, Romain Luc Marie Gosmini, Christopher Gaëtan Housseman, Koen Karel Jansen, Jianguo Ji, Philip R. Kym, Jean-Michel Lefrancois, Oscar Mammoliti, Christel Jeanne Marie Menet, Nuria Merayo Merayo, Gregory John Robert Newsome, Adeline Marie Elise Palisse, Sachin V. Patel, Matthieu Rafaël Pizzonero, Anurupa Shrestha, Elizabeth C. Swift, Steven Emiel Van der Plas, Xueqing Wang, Ann de Blieck
-
Patent number: 10130622Abstract: A corrector agent capable of stabilizing a newly synthesized cystic fibrosis transmembrane conductance regulator (CFTR) protein, useful in the treatment of cystic fibrosis.Type: GrantFiled: October 7, 2016Date of Patent: November 20, 2018Assignees: AbbVie S.á.r.l., Galapagos NVInventors: Rhalid Akkari, Luke Jonathan Alvey, Xavier Marie Bock, Brian S. Brown, Pieter Isabelle Roger Claes, Marlon D. Cowart, Katja E. Conrath, Douglas Cyr, Elsa De Lemos, Gert Jules Hector De Wilde, Nicolas Desroy, Béranger Duthion, Gregory A. Gfesser, Romain Luc Marie Gosmini, Christopher Gaëtan Housseman, Koen Karel Jansen, Jianguo Ji, Philip R. Kym, Jean-Michel Lefrancois, Oscar Mammoliti, Christel Jeanne Marie Menet, Nuria Merayo Merayo, Gregory John Robert Newsome, Adeline Marie Elise Palisse, Sachin V. Patel, Mathieu Rafaël Pizzonero, Anurupa Shrestha, Elizabeth C. Swift, Chris Tse, Steven Emiel Van der Plas, Xueqing Wang
-
Patent number: 9981910Abstract: The invention discloses compounds of Formula (I) wherein R1, R2, R2A, R3, R3A, R4, R4A, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.Type: GrantFiled: October 5, 2017Date of Patent: May 29, 2018Assignees: AbbVie S.á.r.l., Galapagos NVInventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Elsa De Lemos, Nicolas Desroy, Béranger Duthion, Gregory A. Gfesser, Stephen N. Greszler, Christopher Gaëtan Housseman, John R. Koenig, Philip R. Kym, Bo Liu, Marc J. Scanio, Xenia Searle, Xueqing Wang, Ming C. Yeung, Gang Zhao
-
Publication number: 20180105522Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).Type: ApplicationFiled: December 15, 2017Publication date: April 19, 2018Inventors: Rhalid Akkari, Luke Jonathan Alvey, Xavier Marie Bock, Brian S. Brown, Pieter Isabelle Roger Claes, Marlon D. Cowart, Elsa De Lemos, Nicolas Desroy, Béranger Duthion, Gregory A. Gfesser, Romain Luc Marie Gosmini, Christopher Gaëtan Housseman, Koen Karel Jansen, Jianguo Ji, Philip R. Kym, Jean-Michel Lefrancois, Oscar Mammoliti, Christel Jeanne Marie Menet, Nuria Merayo Merayo, Gregory John Robert Newsome, Adeline Marie Elise Palisse, Sachin V. Patel, Matthieu Rafaël Pizzonero, Anurupa Shrestha, Elizabeth C. Swift, Steven Emiel Van der Plas, Xueqing Wang, Ann de Blieck
-
Publication number: 20180099931Abstract: The invention discloses compounds of Formula (I) wherein R1, R2, R2A, R3, R3A, R4, R4A, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.Type: ApplicationFiled: October 5, 2017Publication date: April 12, 2018Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Elsa De Lemos, Nicolas Desroy, Béranger Duthion, Gregory A. Gfesser, Stephen N. Greszler, Christopher Gaëtan Housseman, John R. Koenig, Philip R. Kym, Bo Liu, Marc J. Scanio, Xenia Searle, Xueqing Wang, Ming C. Yeung, Gang Zhao
-
Patent number: 9890158Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).Type: GrantFiled: October 7, 2016Date of Patent: February 13, 2018Assignees: AbbVie S.á.r.l., Galapagos NVInventors: Rhalid Akkari, Luke Jonathan Alvey, Xavier Marie Bock, Brian S. Brown, Pieter Isabelle Roger Claes, Marlon D. Cowart, Elsa De Lemos, Nicolas Desroy, Béranger Duthion, Gregory A. Gfesser, Romain Luc Marie Gosmini, Christopher Gaëtan Housseman, Koen Karel Jansen, Jianguo Ji, Philip R. Kym, Jean-Michel Lefrancois, Oscar Mammoliti, Christel Jeanne Marie Menet, Nuria Merayo Merayo, Gregory John Robert Newsome, Adeline Marie Elise Palisse, Sachin V. Patel, Matthieu Rafaël Pizzonero, Anurupa Shrestha, Elizabeth C. Swift, Steven Emiel Van der Plas, Xueqing Wang, Ann de Blieck
-
Patent number: 9796711Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, and R4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).Type: GrantFiled: October 7, 2016Date of Patent: October 24, 2017Assignees: AbbVie S.á.r.l., Galapagos NVInventors: Rhalid Akkari, Luke Jonathan Alvey, Xavier Marie Bock, Pieter Isabelle Roger Claes, Marlon D. Cowart, Elsa De Lemos, Nicolas Desroy, Béranger Duthion, Gregory A. Gfesser, Romain Luc Marie Gosmini, Christopher Gaëtan Housseman, Koen Karel Jansen, Jianguo Ji, Philip R. Kym, Jean-Michel Lefrancois, Oscar Mammoliti, Christel Jeanne Marie Menet, Gregory John Robert Newsome, Adeline Marie Elise Palisse, Sachin V Patel, Mathieu Rafaël Pizzonero, Anurupa Shrestha, Elizabeth C. Swift, Steven Emiel Van der Plas, Xueqing Wang
-
Publication number: 20170101406Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, and R4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).Type: ApplicationFiled: October 7, 2016Publication date: April 13, 2017Inventors: Rhalid Akkari, Luke Jonathan Alvey, Xavier Marie Bock, Pieter Isabelle Roger Claes, Marlon D. Cowart, Elsa De Lemos, Nicolas Desroy, Béranger Duthion, Gregory A. Gfesser, Romain Luc Marie Gosmini, Christopher Gaëtan Housseman, Koen Karel Jansen, Jianguo Ji, Philip R. Kym, Jean-Michel Lefrancois, Oscar Mammoliti, Christel Jeanne Marie Menet, Gregory John Robert Newsome, Adeline Marie Elise Palisse, Sachin V Patel, Mathieu Rafaël Pizzonero, Anurupa Shrestha, Elizabeth C. Swift, Steven Emiel Van der Plas, Xueqing Wang
-
Publication number: 20170100386Abstract: A corrector agent capable of stabilizing a newly synthesized cystic fibrosis transmembrane conductance regulator (CFTR) protein, useful in the treatment of cystic fibrosis.Type: ApplicationFiled: October 7, 2016Publication date: April 13, 2017Inventors: Rhalid Akkari, Luke Jonathan Alvey, Xavier Marie Bock, Brian S. Brown, Pieter Isabelle Roger Claes, Marlon D. Cowart, Katja E. Conrath, Douglas Cyr, Elsa De Lemos, Gert Jules Hector De Wilde, Nicolas Desroy, Béranger Duthion, Gregory A. Gfesser, Romain Luc Marie Gosmini, Christopher Gaëtan Housseman, Koen Karel Jansen, Jianguo Ji, Philip R. Kym, Jean-Michel Lefrancois, Oscar Mammoliti, Christel Jeanne Marie Menet, Nuria Merayo Merayo, Gregory John Robert Newsome, Adeline Marie Elise Palisse, Sachin V. Patel, Mathieu Rafaël Pizzonero, Anurupa Shrestha, Elizabeth C. Swift, Chris Tse, Steven Emiel Van der Plas, Xueqing Wang
-
Publication number: 20170101405Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).Type: ApplicationFiled: October 7, 2016Publication date: April 13, 2017Inventors: Rhalid Akkari, Luke Jonathan Alvey, Xavier Marie Bock, Brian S. Brown, Pieter Isabelle Roger Claes, Marlon D. Cowart, Elsa De Lemos, Nicolas Desroy, Béranger Duthion, Gregory A. Gfesser, Romain Luc Marie Gosmini, Christopher Gaëtan Housseman, Koen Karel Jansen, Jianguo Ji, Philip R. Kym, Jean-Michel Lefrancois, Oscar Mammoliti, Christel Jeanne Marie Menet, Nuria Merayo Merayo, Gregory John Robert Newsome, Adeline Marie Elise Palisse, Sachin V. Patel, Matthieu Rafaël Pizzonero, Anurupa Shrestha, Elizabeth C. Swift, Steven Em iel Van der Plas, Xueqing Wang, Ann de Blieck